BR102016016449A2 - carbohydrate antigen-linked viral particle for differential diagnosis of nasturtium, method, kit, vaccine and use - Google Patents

carbohydrate antigen-linked viral particle for differential diagnosis of nasturtium, method, kit, vaccine and use

Info

Publication number
BR102016016449A2
BR102016016449A2 BR102016016449A BR102016016449A BR102016016449A2 BR 102016016449 A2 BR102016016449 A2 BR 102016016449A2 BR 102016016449 A BR102016016449 A BR 102016016449A BR 102016016449 A BR102016016449 A BR 102016016449A BR 102016016449 A2 BR102016016449 A2 BR 102016016449A2
Authority
BR
Brazil
Prior art keywords
kit
vaccine
nasturtium
viral particle
present
Prior art date
Application number
BR102016016449A
Other languages
Portuguese (pt)
Inventor
Ferreira Marques Alexandre
Tostes Gazzinelli Ricardo
Original Assignee
Univ Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais filed Critical Univ Minas Gerais
Priority to BR102016016449A priority Critical patent/BR102016016449A2/en
Priority to PCT/IB2017/054219 priority patent/WO2018011739A1/en
Publication of BR102016016449A2 publication Critical patent/BR102016016449A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

partícula viral ligada a antígeno carboidrato para diagnóstico diferencial da doença de chagas, método, kit vacina e uso. a presente invenção trata de um bacteriógago qß-vlp acoplado a várias cópias do trissacarídeo sintético alfa-gal (gala1-3galß1-4glcnacr), denominado de qß-agal, associado ou não a proteínas recombinantes, como a adasp-2, e seu uso como partícula vacinal. a presente invenção também descreve um método e um kit para detecção de anticorpos anti-alfa-gal por elisa, para diagnóstico da doença de chagas. o método da presente invenção aumenta a captura de anticorpos produzidos por exposição a t. cruzi, apresentando alta sensibilidade e seletividade e possibilitando a detecção da infecção e o acompanhamento da efetividade do tratamento com benznidazol.carbohydrate antigen-linked viral particle for differential diagnosis of chagas disease, method, vaccine kit and use. The present invention deals with a qß-vlp bacteriophage coupled to several copies of the synthetic alpha-gal trisaccharide (gala1-3galß1-4glcnacr), called qß-agal, whether or not associated with recombinant proteins, such as adasp-2, and its use. as a vaccine particle. The present invention also discloses a method and kit for detection of anti-alpha-gal antibodies by elisa for the diagnosis of nasturtium disease. The method of the present invention increases the capture of antibodies produced by exposure to t. cruzi, presenting high sensitivity and selectivity and enabling detection of infection and monitoring the effectiveness of treatment with benznidazole.

BR102016016449A 2016-07-15 2016-07-15 carbohydrate antigen-linked viral particle for differential diagnosis of nasturtium, method, kit, vaccine and use BR102016016449A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR102016016449A BR102016016449A2 (en) 2016-07-15 2016-07-15 carbohydrate antigen-linked viral particle for differential diagnosis of nasturtium, method, kit, vaccine and use
PCT/IB2017/054219 WO2018011739A1 (en) 2016-07-15 2017-07-12 Virus particle linked to carbohydrate antigen for differential diagnosis of chagas disease, method, kit, vaccine and use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102016016449A BR102016016449A2 (en) 2016-07-15 2016-07-15 carbohydrate antigen-linked viral particle for differential diagnosis of nasturtium, method, kit, vaccine and use

Publications (1)

Publication Number Publication Date
BR102016016449A2 true BR102016016449A2 (en) 2018-01-23

Family

ID=60952339

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102016016449A BR102016016449A2 (en) 2016-07-15 2016-07-15 carbohydrate antigen-linked viral particle for differential diagnosis of nasturtium, method, kit, vaccine and use

Country Status (2)

Country Link
BR (1) BR102016016449A2 (en)
WO (1) WO2018011739A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2724730A1 (en) * 2012-10-29 2014-04-30 Institut Pasteur Glycoconjugates and their use as potential vaccines against infection by Shigella Flexneri
US10363319B2 (en) * 2014-10-31 2019-07-30 The Board Of Regents Of The Univerity Of Texas System Glycoconjugates and methods for their use

Also Published As

Publication number Publication date
WO2018011739A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
CO2018009434A2 (en) Dengue anti-virus ns1 protein monoclonal antibodies
CL2019000067A1 (en) New antibodies that specifically bind to Zika virus epitopes and uses thereof.
BR112017010268A2 (en) binding agent; diagnostic composition; diagnostic kit; methods of diagnosing a bacterial infection or differentiating between a bacterial infection and a viral infection; to rule out a bacterial infection in an individual; to rule out a viral infection in an individual; to consider a bacterial infection in an individual; to consider a viral infection in an individual; to distinguish between a bacterial or mixed infection and a viral infection in an individual; to provide a treatment recommendation to an individual; to provide a diagnostic test recommendation to an individual; to rule out an infectious disease; to identify the type of infection; and device for the diagnosis of bacterial infections
CL2017001610A1 (en) Human antibodies to influenza hemagglutinin
BR112018075288A2 (en) methods for diagnosing bacterial and viral infections
BR112017004899A2 (en) misfolded protein detection
EA201301173A1 (en) CLONAL STRAINS OF ATTENUATED VACCINATING VIRUSES AND METHODS OF THEIR USE
BR112015022790A8 (en) bispecific molecule, pharmaceutical composition, method of treating a latent virus infection in an individual in need of such treatment, method of treating a persistent virus infection in an individual in need of such treatment, method of treating a virus infection inactive in an individual in need of such treatment, method to exterminate a cell that contains a viral genome, and method to exterminate a cell that expresses a viral protein
WO2018187706A3 (en) Anti-influenza b virus neuraminidase antibodies and uses thereof
MX2020004674A (en) Antibodies to ¿-synuclein and uses thereof.
BR112019009256A2 (en) methods for treating alport syndrome using methyl bardoxolone or analogs thereof
BR112018075513A2 (en) nucleic acids encoding Zika virus-like particles and their use in vaccines and Zika virus diagnostic testing
BR112014024751A2 (en) clostridium difficile antigens
BR112015021341A2 (en) flavivirus neutralizing antibodies and methods of use
BR112016014010A2 (en) methods for detecting antibodies to wild-type classical swine fever virus (csfv), to differentiate between wild-type csfv-infected animals and animals that have been vaccinated against csfv, and to control a wild-type csfv infection, diagnostic test kit, and, use of a carrier
BR112019000946A8 (en) COMPOUNDS FOR IMAGING TAU PROTEIN AGGREGATES
MY181007A (en) Scale drop disease (sdd) causative virus and derivatives thereof
EA201992317A1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSTIC OF LUNG CANCER
BR112014004261A2 (en) improved vaccine diagnostics
BR102016016449A2 (en) carbohydrate antigen-linked viral particle for differential diagnosis of nasturtium, method, kit, vaccine and use
BR112021013096A2 (en) TREATMENT OF SJÖGREN'S DISEASE WITH NUCLEASE FUSION PROTEINS
WO2017053525A3 (en) Influenza vaccine and therapy
Butler South Korean MERS outbreak is not a global threat
EA201401101A1 (en) METHOD OF LABORATORY DIAGNOSTICS OF PNEUMONIA
EA202191393A1 (en) STABLE VACCINE AGAINST CLOSTRIDIUM DIFFICILE

Legal Events

Date Code Title Description
B11K Dismissal acc. art. 17, par 2 of ipl - pending earlier application (priority claim) definitively shelved
B03F Publication of an application: publication of application definitely dismissed - article 216, par 2 and article 17, par 2 of industr. prop. law